Table 4: Characteristics of patients with ANA and ASMA positive and negative at all three times.

VariablesTotal number of patients
114
ANA always positive
52
ANA always negative
11
ASMA
always positive
2
ASMA always negative
78

Gender (%)
 (i) Male7632 (42.1)8 (10.5)2 (2.6)52 (68.4)
 (ii) Female3820 (52.6)3 (7.9)0 (0)26 (68.4)
0.2 0.6 0.3 1.0
Cause of transplantation
 (i) HBV3913 (33.3)3 (7.7)032 (82.0)
 (ii) HCV5730 (52.6)6 (10.5)2 (3.5)36 (63.1)
 (iii) Other189 (50)2 (11.1)010 (55.5)
0.1 0.8 0.3 0.06
HCC at the time of transplantation
 (i) No7436 (48.6)6 (8.1)0 (0)52 (70.3)
 (ii) Yes4016 (40)5 (12.5)2 (5)26 (65)
0.4 0.4 0.06 0.5
Early liver rejection
 (i) No8738 (43.7)9 (10.5)2 (2.3)61 (70.1)
 (ii) Yes2714 (51.8)2 (7.4)017 (62.9)
P 0.4 0.6 0.4 0.4
Time from transplantation
 (i) >3 months–1 year116 (54.5)1 (9.1)08 (72.7)
 (ii) >1 year–5 years2711 (40.7)5 (18.5)017 (62.9)
 (iii) >5 years–10 years2611 (42.3)1 (3.8)2 (7.7)19 (73.1)
 (iv) >10 years5024 (48)4 (8)034 (68)
0.8 0.3 0.09 0.8
Age group at 0
 (i) ≤50 years157 (46.6)1 (6.6)010 (66.6)
 (ii) >50–60 years3413 (38.2)3 (8.8)1 (2.9)27 (79.4)
 (iii) >60 years6532 (49.2)7 (10.8)1 (1.5)41 (63.1)
0.6 0.8 0.7 0.2
Therapy at the time of the study
 (i) Cyclosporine3219 (59.4)4 (12.5)023 (71.8)
 (ii) FK5526 (47.3)4 (7.3)1 (1.8)36 (65.5)
 (iii) Mycophenolate124 (33.3)0 (0)010 (83.4)
 (iv) Everolimus153 (20)3 (20)1 (6.6)9 (60)
0.06 0.2 0.4 0.5